Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Trial to Evaluate the Safety and Immunogenicity of R21/Matrix-M in a Single and Two Vial Presentation, With Different Immunisation Schedules, and When Co-Administered With EPI Vaccines in African Children

Next Previous
X
Search
Trial Profile

A Phase Ib Trial to Evaluate the Safety and Immunogenicity of R21/Matrix-M in a Single and Two Vial Presentation, With Different Immunisation Schedules, and When Co-Administered With EPI Vaccines in African Children

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Measles and rubella virus vaccine (Primary) ; Poliovirus vaccine (Primary) ; R 21 (Primary) ; Yellow fever vaccine (Primary)
  • Indications Malaria
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 15 May 2024 Planned End Date changed from 1 Aug 2024 to 1 May 2025.
    • 15 May 2024 Planned primary completion date changed from 1 Sep 2023 to 1 May 2025.
    • 15 May 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top